2005;352:1425 35. S3.2.1-15. Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of car- diovascular disease with pravastatin in Japan (MEGA Study): a pro- spective randomised controlled trial. Lancet. 2006;368:1155 63. S3.2.1-16. Yusuf S, Bosch J, Dagenais G, et al. Cholesterol lowering in inter- mediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374:2021 31. S3.2.1-17. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170000 participants in 26 randomised trials. Lancet. 2010;376:1670 81. S3.2.1-18. Naito R, Miyauchi K, Daida H. Racial differences in the cholesterol- lowering effect of statin. J Atheroscler Thromb. 2017;24:19 25. S3.2.1-19. Collins R, Reith C, Emberson J, et al. Interpretation of the evi- dence for the efficacy and safety of statin therapy. Lancet. 2016;388:2532 61. S3.2.1-20. American College of Cardiology. American College of Cardiology LDL-C Manager. Available at: http://tools.acc.org/ldl. Accessed January 8, 2018. 3.2.2. Nonstatin Therapies S3.2.2-1. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387 97. S3.2.2-2. Kashani A, Sallam T, Bheemreddy S, et al. Review of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials. Am J Cardiol. 2008;101:1606 13. S3.2.2-3. Khan AR, Bavishi C, Riaz H, et al. Increased risk of adverse neu- rocognitive outcomes with proprotein convertase subtilisin-kexin type 9 inhibitors. Circ Cardiovasc Qual Outcomes. 2017;10: e003153. S3.2.2-4. Robinson JG, Rosenson RS, Farnier M, et al. Safety of very low low- density lipoprotein cholesterol levels with alirocumab: pooled data from randomized trials. J Am Coll Cardiol. 2017;69:471 82. S3.2.2-5. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clini- cal outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713 22. S3.2.2-6. 